Treatment for H. pylori Positive 55-Year-Old Female
For this treatment-naive patient, initiate 14-day bismuth quadruple therapy (BQT) consisting of bismuth ~300mg four times daily, metronidazole 500mg three times daily, tetracycline 500mg four times daily, and a proton pump inhibitor twice daily. This is the preferred first-line regimen when antibiotic susceptibility is unknown 1.
First-Line Treatment Algorithm
The 2024 ACG guidelines establish BQT as the preferred empiric therapy because clarithromycin, levofloxacin, and metronidazole resistance now exceeds 30% in North America 1. This represents a critical shift from older approaches that relied on clarithromycin-based triple therapy.
Alternative First-Line Options
If BQT is not feasible, two alternatives exist:
- Rifabutin triple therapy: rifabutin 150-300mg daily, amoxicillin 1g twice daily, PPI twice daily for 14 days (only if no penicillin allergy) 1
- Potassium-competitive acid blocker (PCAB) dual therapy for 14 days (if no penicillin allergy) 1
Concomitant therapy (clarithromycin 500mg twice daily, amoxicillin 1g twice daily, metronidazole 500mg twice daily, PPI twice daily for 14 days) is another option 2, though its effectiveness is compromised by high clarithromycin resistance.
Critical Treatment Principles
Duration Matters
All regimens must be given for 14 days, not 10 days 1, 2. The 10-day Pylera® formulation was approved for marketing advantage without comparative studies and is suboptimal, particularly in populations with metronidazole resistance 3.
PPI Dosing and Timing
- Standard PPI doses: pantoprazole 40mg, lansoprazole 30mg, omeprazole 20mg, esomeprazole 20mg, rabeprazole 20mg
- Administer 30 minutes before eating on an empty stomach
- Avoid concurrent use of H2-receptor antagonists 4
Bismuth Quadruple Therapy Nuances
BQT uniquely overcomes metronidazole resistance by increasing dose and duration 3. While less tolerable than other regimens, it remains highly effective when optimized to 14 days with adequate metronidazole dosing (1.6-2 grams daily) 3.
Post-Treatment Management
Confirm eradication with test-of-cure using urea breath test or stool antigen test at least 4 weeks after completing therapy 1. Do not use serology for confirmation as it cannot distinguish active from past infection 5.
If First-Line Therapy Fails
For treatment-experienced patients:
- If not previously treated with optimized BQT: Use optimized 14-day BQT 1
- If previously treated with optimized BQT: Use rifabutin triple therapy for 14 days 1
- After two failed therapies: Obtain antimicrobial susceptibility testing before selecting subsequent regimens 4, 1
Salvage Therapy Caution
Never use clarithromycin or levofloxacin-containing regimens for salvage therapy unless antibiotic susceptibility is confirmed 1. Resistance rates exceed 30% for both agents, making empiric use ineffective 1.
Common Pitfalls to Avoid
- Do not use 7-day regimens: Eradication rates are significantly lower than 14-day courses 6
- Do not assume clarithromycin triple therapy is adequate: This should only be used in areas with documented low clarithromycin resistance (<15%), which no longer applies to most of North America 2
- Do not skip test-of-cure: This patient requires confirmation of eradication given the high stakes of persistent infection (peptic ulcer disease, gastric cancer risk) 1
- Do not use probiotics as adjunctive therapy: These are of unproven benefit and should be considered experimental 4